# Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer

> **NCT01069653** · PHASE1 · COMPLETED · sponsor: **Shiga University** · enrollment: 9 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** HLA-A*2402-restricted CDCA1 and KIF20A peptides

## Key facts

- **NCT ID:** NCT01069653
- **Lead sponsor:** Shiga University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2019-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01069653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01069653, "Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01069653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*